The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy

This prospective case-control study was conducted between 1 January 2022 and 31 December 2022 at Bursa Yuksek Ihtisas Training and Research Hospital. The study was conducted with pregnant women between ages of 18-45 who were diagnosed with preeclampsia in the second trimester. This study was conducted with total 156 pregnant women. participants were grouped according to the presence of preeclampsia; Group1: Patients diagnosed with preeclampsia between 20-28 weeks (study group) (n:78) , Group 2: Healthy pregnant women between 20-28 weeks without a diagnosis of preeclampsia ( control group) (n:78) . As soon as preeclampsia is diagnosed and before any treatment was started, maternal serum samples were collected in the Cathepsin B and Pentraxin 3 kit in amounts suitable for the study. The samples obtained were kept in biochemistry laboratory at -80 degrees until the study was conducted. After all samples were collected, Cathepsin B and Pentraxin 3 values were measured by ELISA method.

Inclusion criteria

• Singleton pregnancy
• Pregnant women diagnosed with preeclampsia between 20-28 weeks of gestation
• Healthy pregnant women between 20-28 weeks of gestation who want to be involved in the study.

Exclusion criteria

• Multiple pregnancies
• Pregnant women who gave birth below 24 weeks of gestation
• Pregnant women diagnosed with other hypertensive diseases of pregnancy other than preeclampsia ( gestational hypertension, chronic hypertension, superimposed hypertension)
• Pregnant women with chromosomal or congenital anomalies in the fetus
• Women with a known infective or autoimmune disease before pregnancy